MediLink, a Roche Holding collaborator, announced positive Phase III trial results for Tam-Peli in relapsed small-cell lung cancer and obtained FDA priority review.
MediLink, a collaborator of Roche Holding, reported positive Phase III trial results for its Tam-Peli therapy in relapsed small-cell lung cancer.
The company also secured FDA priority review for the treatment. Further verified details were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
